ROCHE EXTENDS SYNTEX OFFER
Swiss drug company Roche has announced that Roche Capital Corporation has extended its offer to purchase all outstanding shares of common stock of US pharmaceutical company Syntex (Marketletters passim) for $24 in cash until August 3, 1994.
The US Federal Trade Commission has requested additional information be made available and the extension will provide time to comply with this request.
Roche Capital has also extended the expiration for the tender offer until 12 midnight, New York City time on August 3, 1994. It had previously been set to expire on July 1, 1994. It has been suggested that this could be extended again in order to meet with FTC's request.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze